BMPR2_HUMAN » Bone morphogenetic protein receptor type-2

BMPR2_HUMAN » Bone morphogenetic protein receptor type-2
Magnify BMPR2_HUMAN » Bone morphogenetic protein receptor type-2Enlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
BMPR2_HUMAN » Bone morphogenetic protein receptor type-2 » BMP type-2 receptor; BMPR-2; Bone morphogenetic protein receptor type II;BMP type II receptor; BMPR-II;
Hydrophobic Thickness 34.0 ± 3.2 Å
Tilt Angle 29 ± 1°
ΔGtransfer -27.6 kcal/mol
ΔGfold -21.2 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC, HMDB
Topology Out
TM Segments 148-172 (147-175)
Pathways

Cytokine-cytokine receptor interaction (KEGG)

Hippo signaling pathway (KEGG)

Signal Transduction (Reactome)

TGF-beta signaling pathway (KEGG)

PDB 3g2f (189-517), 2hlq (33-131)
OPM none
Complexes none
Interactions

ACV1B, Complex: BMPR2:ACV1B, PubMed

ACVR1, Complex: BMPR2:ACVR1, PubMed

BMR1A, Complex: BMR1A:BMPR2, PubMed

BMR1B, Complex: BMPR2:BMR1B, PubMed

CD44, Complex: CD44:BMPR2, PubMed

MERTK, Complex: MERTK:BMPR2, PubMed

TGFR1, Complex: TGFR1:BMPR2, PubMed

Domains

AA: 33-127, PDBID: 2HLQ, Subunit A, Seq Identity:100%, Activin types I and II receptor domain

AA: 203-501, PDBID: 3G2F, Subunit B, Seq Identity:100%, Protein kinase domain

UniProt annotation for BMPR2_HUMAN » Bone morphogenetic protein receptor type-2
FUNCTION: On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP-7, BMP-2 and, less efficiently, BMP-4. Binding is weak but enhanced by the presence of type I receptors for BMPs.

CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor- protein] phosphate.

SUBUNIT: Interacts with GDF5.

TISSUE SPECIFICITY: Highly expressed in heart and liver.

DISEASE: Pulmonary hypertension, primary, 1 (PPH1) OMIM: A rare disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs. Note=The disease is caused by mutations affecting the gene represented in this entry.

DISEASE: Pulmonary venoocclusive disease 1, autosomal dominant (PVOD1) OMIM: A disease characterized by widespread fibrous obstruction and intimal thickening of septal veins and preseptal venules, a low diffusing capacity for carbon monoxide, occult alveolar hemorrhage, and nodular ground-glass opacities, septal lines and lymph node enlargement showed by high-resolution computed tomography of the chest. It is frequently associated with pulmonary capillary dilatation and proliferation, and is a rare and devastating cause of pulmonary hypertension. Note=The disease is caused by mutations affecting the gene represented in this entry.

UniProt features for BMPR2_HUMAN » Bone morphogenetic protein receptor type-2
SIGNAL 1 26 Potential.
CHAIN 27 1038 Bone morphogenetic protein receptor type- 2.
DOMAIN 203 504 Protein kinase.
ACT_SITE 333 333 Proton acceptor (By similarity).
DISULFID 34 66 By similarity.
DISULFID 94 117 By similarity.
Amino Acid Sequence for BMPR2_HUMAN » Bone morphogenetic protein receptor type-2
MTSSLQRPWR VPWLPWTILL VSTAAASQNQ ERLCAFKDPY QQDLGIGESR ISHENGTILC SKGSTCYGLW EKSKGDINLV KQGCWSHIGD PQECHYEECV VTTTPPSIQN GTYRFCCCST DLCNVNFTEN FPPPDTTPLS PPHSFNRDET IIIALASVSV LAVLIVALCF GYRMLTGDRK QGLHSMNMME AAASEPSLDL DNLKLLELIG RGRYGAVYKG SLDERPVAVK VFSFANRQNF INEKNIYRVP LMEHDNIARF IVGDERVTAD GRMEYLLVME YYPNGSLCKY LSLHTSDWVS SCRLAHSVTR GLAYLHTELP RGDHYKPAIS HRDLNSRNVL VKNDGTCVIS DFGLSMRLTG NRLVRPGEED NAAISEVGTI RYMAPEVLEG AVNLRDCESA LKQVDMYALG LIYWEIFMRC TDLFPGESVP EYQMAFQTEV GNHPTFEDMQ VLVSREKQRP KFPEAWKENS LAVRSLKETI EDCWDQDAEA RLTAQCAEER MAELMMIWER NKSVSPTVNP MSTAMQNERN LSHNRRVPKI GPYPDYSSSS YIEDSIHHTD SIVKNISSEH SMSSTPLTIG EKNRNSINYE RQQAQARIPS PETSVTSLST NTTTTNTTGL TPSTGMTTIS EMPYPDETNL HTTNVAQSIG PTPVCLQLTE EDLETNKLDP KEVDKNLKES SDENLMEHSL KQFSGPDPLS STSSSLLYPL IKLAVEATGQ QDFTQTANGQ ACLIPDVLPT QIYPLPKQQN LPKRPTSLPL NTKNSTKEPR LKFGSKHKSN LKQVETGVAK MNTINAAEPH VVTVTMNGVA GRNHSVNSHA ATTQYANGTV LSGQTTNIVT HRAQEMLQNQ FIGEDTRLNI NSSPDEHEPL LRREQQAGHD EGVLDRLVDR RERPLEGGRT NSNNNNSNPC SEQDVLAQGV PSTAADPGPS KPRRAQRPNS LDLSATNVLD GSSIQIGEST QDGKSGSGEK IKKRVKTPYS LKRWRPSTWV ISTESLDCEV NNNGSNRAVH SKSSTAVYLA EGGTATTMVS KDIGMNCL